Foundation for Innovative New Diagnostics, Geneva, Switzerland; Department of Medicine, University of California, San Diego, California, USA.
Foundation for Innovative New Diagnostics, Geneva, Switzerland.
Diagn Microbiol Infect Dis. 2020 Oct;98(2):115096. doi: 10.1016/j.diagmicrobio.2020.115096. Epub 2020 May 30.
Robust clinical specimen nucleic acid extraction instrumentation and methods are critical to the performance of downstream molecular diagnostics for the diagnosis of drug-resistant tuberculosis (DR-TB). Currently, there is a high level of interest in sequencing-based solutions for rapid and comprehensive DR-TB testing from primary specimens (i.e., sputum). However, there is no standardized or fully automated sputum extraction system that has been widely implemented for use with Mycobacterium tuberculosis complex-containing sputum specimens. For sequencing-based technologies to be widely adopted in clinical laboratory settings in low- and middle-income countries, automated extraction technologies will be important to enhance scalability and reliability and to standardize performance of the downstream assays. Additionally, the ease of automatic technologies allows for faster uptake in laboratories currently without the expertise or infrastructure to perform manual extractions at the same automated throughput. This work is intended to provide an initial specification comparison of available automated DNA extraction systems that could serve as front-end components for existing and future sequencing approaches and provide the framework for future evaluations.
用于耐药结核病（DR-TB）诊断的下游分子诊断的稳健临床标本核酸提取仪器和方法对于性能至关重要。目前，人们对基于测序的解决方案非常感兴趣，希望能从原始标本（即痰液）中快速全面地检测 DR-TB。然而，目前还没有标准化或完全自动化的痰液提取系统，广泛应用于含结核分枝杆菌复合体的痰液标本。为了使基于测序的技术在中低收入国家的临床实验室环境中得到广泛采用，自动化提取技术对于提高可扩展性和可靠性以及标准化下游检测的性能非常重要。此外，自动技术的易用性使得那些目前没有专业知识或基础设施来以相同的自动化通量进行手动提取的实验室能够更快地采用。这项工作旨在提供现有自动化 DNA 提取系统的初步规格比较，这些系统可以作为现有和未来测序方法的前端组件，并为未来的评估提供框架。
